Eubel Brady & Suttman Asset Management Inc. Has $26.56 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Eubel Brady & Suttman Asset Management Inc. grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 291,165 shares of the medical equipment provider’s stock after acquiring an additional 53,105 shares during the period. Zimmer Biomet accounts for about 3.4% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 9th largest position. Eubel Brady & Suttman Asset Management Inc.’s holdings in Zimmer Biomet were worth $26,557,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Oarsman Capital Inc. raised its position in Zimmer Biomet by 51.8% during the second quarter. Oarsman Capital Inc. now owns 3,053 shares of the medical equipment provider’s stock valued at $278,000 after purchasing an additional 1,042 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Zimmer Biomet by 12.3% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 27,347 shares of the medical equipment provider’s stock worth $2,494,000 after purchasing an additional 3,000 shares in the last quarter. SYM FINANCIAL Corp boosted its position in shares of Zimmer Biomet by 71.8% in the 2nd quarter. SYM FINANCIAL Corp now owns 3,457 shares of the medical equipment provider’s stock worth $315,000 after purchasing an additional 1,445 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Zimmer Biomet by 3.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 30,061 shares of the medical equipment provider’s stock worth $2,742,000 after acquiring an additional 915 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $3,600,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.70% of the company’s stock.

Zimmer Biomet Stock Down 1.9%

Shares of NYSE ZBH opened at $101.18 on Wednesday. The firm has a market cap of $20.04 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The firm’s 50 day moving average price is $101.81 and its 200 day moving average price is $97.63. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the business posted $2.01 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Raymond James Financial lifted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a research report on Friday, October 10th. Evercore ISI dropped their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Finally, Stifel Nicolaus upped their price objective on Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.